Teva In Transition: Generics, Specialty And 'The Space Between'
This article was originally published in Scrip
Executive Summary
In an interview with Scrip's sister publication "The Pink Sheet", President of Global R&D Michael Hayden talked about integrating Allergan generics, Teva's late-stage specialty pipeline and its 17 new therapeutic entities, medicines that bridge generics and specialty medicine.
You may also be interested in...
A New Regime Takes The Reins At Teva
New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.
A New Regime Takes The Reins At Teva
New CEO Kare Schultz has established a new leadership team and structure at the generic drug giant, as head of R&D Michael Hayden, Global Specialty Medicines CEO Rob Koremans and Global Generics Medicines CEO Dipankar Bhattacharjee will all leave at the end of the year.
Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: